Uptake of new hemophilia gene therapies slow as field assesses options

By Deena Beasley (Reuters) - High cost, logistical issues and the prospect of potential treatment advances are holding back adoption of the first gene...

Related Keywords

San Diego ,California ,United States ,American ,America ,Michael Recht ,Caroline Humer ,Bob Lojewski ,Biomarin Roctavian ,Margaret Ragni ,Deena Beasley ,National Bleeding Disorders Foundation ,Pfizer ,Reuters ,American Society Of Hematology ,University Of Pittsburgh ,American Society ,Reporting By Deena Beasley ,Bill Berkrot , ,